Company BeiGene, Ltd.

Equities

BGNE

US07725L1026

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 20/09/2024 am IST			5-day change	1st Jan Change
198.59 ^USD	+0.66%		+1.18%	+10.11%

18/09	JMP Securities Initiates BeiGene at Outperform With $288 Price Target	MT
17/09	BeiGene Receives Israeli Ministry of Health Approval for TEVIMBRA® for the Treatment of Oesophageal Squamous Cell Carcinoma After Prior Chemotherapy	CI

Business description: BeiGene, Ltd.

BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Brutonâs Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The Company has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. It also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc.

Number of employees: 10,000

Sales by Activity: BeiGene, Ltd.

Fiscal Period: December	2019	2020	2021	2022	2023
Pharmaceutical Products	43Cr	31Cr	117.63Cr	141.59Cr	245.88Cr

See all business segments

Geographical breakdown of sales: BeiGene, Ltd.

Fiscal Period: December	2019	2020	2021	2022	2023
United States (U.S)	13Cr	1.82Cr	50Cr	50Cr	112.82Cr
China	22Cr	29Cr	52Cr	84Cr	110.2Cr
Europe	-	-	-	-	20Cr
Rest of World	7.2Cr	-	16Cr	7.33Cr	2.66Cr

See all geographic segments

Managers: BeiGene, Ltd.

Director	Title	Age	Since
John Oyler CEO	Chief Executive Officer	56	28/10/28
Xiao Bin Wu PSD	President	62	01/18/01
Christiane Langer CTO	Chief Tech/Sci/R&D Officer	-	01/21/01
Kyu-Sung Lee CTO	Chief Tech/Sci/R&D Officer	64	01/22/01
Lai Wang CTO	Chief Tech/Sci/R&D Officer	47	01/11/01

See BEIGENE, LTD. governance

Members of the board: BeiGene, Ltd.

Manager	Title	Age	Since
John Oyler CEO	Chief Executive Officer	56	28/10/28
Michael Goller BRD	Director/Board Member	49	01/15/01
Donald Glazer BRD	Director/Board Member	79	01/13/01
Ranjeev Krishana BRD	Director/Board Member	50	01/14/01
Qing Qing Yi BRD	Director/Board Member	52	01/14/01
Xiao Dong Wang FOU	Founder	61	28/10/28
Anthony Hooper BRD	Director/Board Member	69	01/20/01
Corazon Sanders BRD	Director/Board Member	67	24/20/24
Alessandro Riva BRD	Director/Board Member	63	01/22/01
Margaret Dugan BRD	Director/Board Member	67	01/22/01

Composition of the Board of Directors

Shareholders: BeiGene, Ltd.

Name	Equities	%	Valuation
AMGEN INC. 19.53 %	246,269,426	19.53 %	3 691 M $
Capital Research & Management Co. (International Investors) 8.200 %	103,421,157	8.200 %	1 550 M $
John Oyler 6.066 %	76,515,076	6.066 %	1 147 M $
HHLR Advisors Ltd. 5.993 %	75,588,463	5.993 %	1 133 M $
Xiao Dong Wang 1.628 %	20,532,185	1.628 %	308 M $

Name	Equities	%	Valuation
Penghua Fund Management Co., Ltd. 6.339 %	7,293,081	6.339 %	150 M $
Wanjia Asset Management Co., Ltd. 4.489 %	5,165,056	4.489 %	106 M $
ICBC Credit Suisse Asset Management Co., Ltd. 4.042 %	4,650,382	4.042 %	95 M $
Bank of China Investment Management Co., Ltd. 2.640 %	3,037,160	2.640 %	62 M $
Bosera Asset Management Co., Ltd. 2.328 %	2,678,498	2.328 %	55 M $

Name	Equities	%	Valuation
Baker Bros. Advisors LP 10.89 %	10,568,897	10.89 %	2 027 M $
Capital Research & Management Co. (International Investors) 7.229 %	7,013,568	7.229 %	1 345 M $
HHLR Advisors Ltd. (Cayman Islands) 5.336 %	5,176,906	5.336 %	993 M $
PRIMECAP Management Co. 5.139 %	4,986,289	5.139 %	956 M $
Baillie Gifford & Co. 3.795 %	3,681,949	3.795 %	706 M $

List of BEIGENE, LTD. shareholders

Company details: BeiGene, Ltd.

BeiGene Ltd.

94 Solaris Avenue Camana Bay

KY1-1108, George Town

+345-949-4123

http://www.beigene.com

Bio Therapeutic Drugs

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi. ($)
BEIGENE, LTD.	+0.66%	+1.18%	-4.92%	-50.17%	2.1TCr
VERTEX PHARMACEUTICALS INCORPORATED	+0.79%	-0.16%	+33.39%	+157.39%	12TCr
REGENERON PHARMACEUTICALS, INC.	+1.00%	-1.23%	+37.46%	+79.47%	12TCr
ARGENX SE	+1.37%	-1.95%	-1.23%	+72.15%	3.16TCr
BIONTECH SE	-2.69%	+7.15%	+1.88%	-66.81%	2.97TCr
SUMMIT THERAPEUTICS INC.	-5.70%	-15.51%	+1,131.91%	+263.01%	1.93TCr
GENMAB A/S	+0.31%	-2.43%	-32.19%	-34.63%	1.67TCr
WUXI APPTEC CO., LTD.	+1.65%	+5.55%	-49.78%	-73.31%	1.61TCr
VAXCYTE, INC.	+0.50%	+2.62%	+133.28%	+357.68%	1.44TCr
INSMED INCORPORATED	+2.88%	+1.43%	+184.95%	+188.24%	1.26TCr
Average	+0.09%	+2.01%	+143.48%	+89.30%	4.09TCr
Weighted average by Cap.	+0.41%	+1.09%	+81.65%	+96.44%